Search results
J&J’s Tremfya meets endpoints in Phase III ulcerative colitis trial
Clinical Trials Arena via Yahoo Finance· 4 days agoJ&J’s Tremfya is expected to be the successor to the company’s IL-12/IL-23 inhibitor Stelara...
J&J’s Tremfya superior to Stelara in Phase II/III Chron’s disease trials
Clinical Trials Arena via Yahoo Finance· 3 days agoThe Phase II/III trial pitted Tremfya against J&J’s Stelara in adult patients with moderately to...
IBD Stock Of The Day Eli Lilly Breaks Out On Its Way To A Record High
Investor's Business Daily· 3 days agoIn comparison, just 27.9% of Stelara patients reached the same mark. Safety Is In Line With Earlier...
Johnson & Johnson shares maintain outperform rating at RBC on TREMFYA potential By Investing.com
Investing.com· 3 days agoThe company has recently filed for approval of TREMFYA as a treatment for Ulcerative Colitis in...
Lilly (LLY) Hits Record High on Crohn's Disease Study Data
Zacks via Yahoo Finance· 3 days agoFollowing the results announcement, shares of Lilly hit an all-time high price...Investment Research...
Alvotech (NYSE:ALVO) Releases Quarterly Earnings Results, Misses Estimates By $0.81 EPS
ETF DAILY NEWS· 1 day agoAlvotech (NYSE:ALVO – Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($0.89) earnings per share for the quarter, missing analysts’ consensus estimates ...
What to know about biologics for Crohn's disease
Medical News Today· 2 days agoCrohn’s disease biologics are medications created using components of living organisms. Crohn’s disease (CD), along with ulcerative colitis, is one of...
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
Morningstar· 4 days ago“We are proud to make SIMLANDI available in the U.S. to patients and providers,” said Thomas Rainey, Senior Vice President...
Guselkumab Continues Winning Streak in Crohn's Disease
MedPage Today· 3 days agoInduction and maintenance treatment with guselkumab (Tremfya) demonstrated its safety and efficacy...